目的:分析抗氧化中药参乌胶囊(Shenwu capsule, SW)、二苯乙烯苷(tetrahydroxystilbene glucoside, TSG)对晶状体老化过程中脂质过氧化及抗氧化能力的影响.方法:雄性SD大鼠96只,分为增龄组及中药干预组,增龄组按月龄不同分为1,3,6,12,18,24共6组,每组10只;中药干预组分为参乌胶囊低剂量[SW(L)]、高剂量[SW(H)]、二苯乙烯苷低剂量[TSG(L)]、高剂量[TSG(H)]4组,分别为10,8,10,8只;药物十预组大鼠均为24mo龄,从21mo龄开始,SW(L),SW(H)组分别给予参乌胶囊0.8g/kg和1.6g/kg灌胃;TSG(L),TSG(H)组分别给予TSG0.03g/kg和0.06g/kg灌胃;老年对照组给予等体积蒸馏水灌胃,每日1次,至24mo,共3mo.处死动物取出眼球,自赤道部切开眼球,完整取出晶状体,采用硫代巴比妥酸比色法与化学发光法检测各组大鼠晶状体组织中谷胱甘肽(glutathione, GSH)、超氧化物岐化酶(superoxide dismutase, SOD)、丙二醛(malondialdehyde, MDA)含量.结果:大鼠晶状体GSH含量1,3,6,12,18,24mo龄、SW(L),SW(H),TSG(L),TSG(H)分另为30.5±7.4,33.3±6.1,29.0±3.1,28.6±4.8,22.0±4.2,20.5±3.2,21.9±3.2,23.1±5.1,20.2±4.4,18.8±2.5mg/gpr;增龄组GSH含量F检验P<0.01,GSH含量与月龄负相关(P<0.01),各用药组与24mo龄组GSH含量F检验P>0.05.大鼠晶状体SOD含量1,3,6,12,18,24mo龄、SW(L),SW(H),TSG(L),TSG(H)分另为41.1±2.1,42.3±2.7,38.6±3.0,38.7±5.2,34.1±1.8,31.9±4.9,30.2±3.2,32.7±3.3,29.8±3.3,32.5±6.0μkat/gpr;增龄组SOD含量F检验P<0.01,SOD含量与月龄负相关(P<0.01).各用药组与24mo组SOD含量F检验P>0.05.大鼠晶状体MDA含量1,3,6,12,18,24mo龄、SW(L),SW(H),TSG(L),TSG(H)分另为49.6±4.4,52.2±3.8,53.1±6.4,53.6±4.7,59.8±4.2,62.2±3.9,61.6±2.9,63.6±5.8,58.1±13.6,57.9±7.6nmol/gpr;增龄组MDA含量F检验P<0.01,MDA含量与月龄正相关(P<0.01),各用药组与24mo组MDA含量F检验P>0.05.结论:大鼠晶状体GSH,SOD及MDA随年龄增长分别呈降低、降低、升高趋势,抗氧化能力下降之后抗氧化药物对此无预防作用.
目的:分析抗氧化中藥參烏膠囊(Shenwu capsule, SW)、二苯乙烯苷(tetrahydroxystilbene glucoside, TSG)對晶狀體老化過程中脂質過氧化及抗氧化能力的影響.方法:雄性SD大鼠96隻,分為增齡組及中藥榦預組,增齡組按月齡不同分為1,3,6,12,18,24共6組,每組10隻;中藥榦預組分為參烏膠囊低劑量[SW(L)]、高劑量[SW(H)]、二苯乙烯苷低劑量[TSG(L)]、高劑量[TSG(H)]4組,分彆為10,8,10,8隻;藥物十預組大鼠均為24mo齡,從21mo齡開始,SW(L),SW(H)組分彆給予參烏膠囊0.8g/kg和1.6g/kg灌胃;TSG(L),TSG(H)組分彆給予TSG0.03g/kg和0.06g/kg灌胃;老年對照組給予等體積蒸餾水灌胃,每日1次,至24mo,共3mo.處死動物取齣眼毬,自赤道部切開眼毬,完整取齣晶狀體,採用硫代巴比妥痠比色法與化學髮光法檢測各組大鼠晶狀體組織中穀胱甘肽(glutathione, GSH)、超氧化物岐化酶(superoxide dismutase, SOD)、丙二醛(malondialdehyde, MDA)含量.結果:大鼠晶狀體GSH含量1,3,6,12,18,24mo齡、SW(L),SW(H),TSG(L),TSG(H)分另為30.5±7.4,33.3±6.1,29.0±3.1,28.6±4.8,22.0±4.2,20.5±3.2,21.9±3.2,23.1±5.1,20.2±4.4,18.8±2.5mg/gpr;增齡組GSH含量F檢驗P<0.01,GSH含量與月齡負相關(P<0.01),各用藥組與24mo齡組GSH含量F檢驗P>0.05.大鼠晶狀體SOD含量1,3,6,12,18,24mo齡、SW(L),SW(H),TSG(L),TSG(H)分另為41.1±2.1,42.3±2.7,38.6±3.0,38.7±5.2,34.1±1.8,31.9±4.9,30.2±3.2,32.7±3.3,29.8±3.3,32.5±6.0μkat/gpr;增齡組SOD含量F檢驗P<0.01,SOD含量與月齡負相關(P<0.01).各用藥組與24mo組SOD含量F檢驗P>0.05.大鼠晶狀體MDA含量1,3,6,12,18,24mo齡、SW(L),SW(H),TSG(L),TSG(H)分另為49.6±4.4,52.2±3.8,53.1±6.4,53.6±4.7,59.8±4.2,62.2±3.9,61.6±2.9,63.6±5.8,58.1±13.6,57.9±7.6nmol/gpr;增齡組MDA含量F檢驗P<0.01,MDA含量與月齡正相關(P<0.01),各用藥組與24mo組MDA含量F檢驗P>0.05.結論:大鼠晶狀體GSH,SOD及MDA隨年齡增長分彆呈降低、降低、升高趨勢,抗氧化能力下降之後抗氧化藥物對此無預防作用.
목적:분석항양화중약삼오효낭(Shenwu capsule, SW)、이분을희감(tetrahydroxystilbene glucoside, TSG)대정상체노화과정중지질과양화급항양화능력적영향.방법:웅성SD대서96지,분위증령조급중약간예조,증령조안월령불동분위1,3,6,12,18,24공6조,매조10지;중약간예조분위삼오효낭저제량[SW(L)]、고제량[SW(H)]、이분을희감저제량[TSG(L)]、고제량[TSG(H)]4조,분별위10,8,10,8지;약물십예조대서균위24mo령,종21mo령개시,SW(L),SW(H)조분별급여삼오효낭0.8g/kg화1.6g/kg관위;TSG(L),TSG(H)조분별급여TSG0.03g/kg화0.06g/kg관위;노년대조조급여등체적증류수관위,매일1차,지24mo,공3mo.처사동물취출안구,자적도부절개안구,완정취출정상체,채용류대파비타산비색법여화학발광법검측각조대서정상체조직중곡광감태(glutathione, GSH)、초양화물기화매(superoxide dismutase, SOD)、병이철(malondialdehyde, MDA)함량.결과:대서정상체GSH함량1,3,6,12,18,24mo령、SW(L),SW(H),TSG(L),TSG(H)분령위30.5±7.4,33.3±6.1,29.0±3.1,28.6±4.8,22.0±4.2,20.5±3.2,21.9±3.2,23.1±5.1,20.2±4.4,18.8±2.5mg/gpr;증령조GSH함량F검험P<0.01,GSH함량여월령부상관(P<0.01),각용약조여24mo령조GSH함량F검험P>0.05.대서정상체SOD함량1,3,6,12,18,24mo령、SW(L),SW(H),TSG(L),TSG(H)분령위41.1±2.1,42.3±2.7,38.6±3.0,38.7±5.2,34.1±1.8,31.9±4.9,30.2±3.2,32.7±3.3,29.8±3.3,32.5±6.0μkat/gpr;증령조SOD함량F검험P<0.01,SOD함량여월령부상관(P<0.01).각용약조여24mo조SOD함량F검험P>0.05.대서정상체MDA함량1,3,6,12,18,24mo령、SW(L),SW(H),TSG(L),TSG(H)분령위49.6±4.4,52.2±3.8,53.1±6.4,53.6±4.7,59.8±4.2,62.2±3.9,61.6±2.9,63.6±5.8,58.1±13.6,57.9±7.6nmol/gpr;증령조MDA함량F검험P<0.01,MDA함량여월령정상관(P<0.01),각용약조여24mo조MDA함량F검험P>0.05.결론:대서정상체GSH,SOD급MDA수년령증장분별정강저、강저、승고추세,항양화능력하강지후항양화약물대차무예방작용.
